Page last updated: 2024-12-08

cymarine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cymarine: A cardiotonic cardiac glycoside found in STROPHANTHUS. The aglycone is STROPHANTHIN. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID441853
CHEMBL ID1075788
CHEBI ID4037
SCHEMBL ID641739
MeSH IDM0005498
PubMed CID222155
MeSH IDM0005498

Synonyms (60)

Synonym
nsc 7522
cymarin (van)
card-20(22)-enolide, 3-((2,6-dideoxy-3-o-methyl-beta-d-ribo-hexopyranosyl)oxy)-5,14-dihydroxy-19-oxo-, (3beta,5beta)-
wv 90043a
strofantidina cimaroside [italian]
einecs 208-087-9
brn 0101370
stropheantin k
5-beta-card-20(22)-enolide, 3-beta-(beta-d-cymarosyloxy)-5,14-dihydroxy-19-oxo-
strophanthidin-d-cymarosid [german]
k-strophanthin-alpha
ACON0_000820
SMP1_000086
ACON1_001275
MEGXP0_001730 ,
C08859
cymarin
strophanthidin 3-o-beta-d-cymaroside
508-77-0
NCGC00169509-01
cymarin, >=96% (hplc)
AC1L9BRZ ,
CHEMBL1075788 ,
chebi:4037 ,
strofantidina cimaroside
unii-uk3ls8435e
5-18-05-00129 (beilstein handbook reference)
strophanthidin-d-cymarosid
uk3ls8435e ,
BRD-K08486545-001-01-8
3.beta.-((2,6-dideoxy-3-o-methyl-.beta.-d-ribo-hexopyranosyl)oxy)-5,14-dihydroxy-19-oxo-5.beta.,14.beta.-card-20(22)-enolide
cymarin [mart.]
cymarin [mi]
cymarin [who-dd]
SCHEMBL641739
stock1n-53317
(3s,5s,8r,9s,10s,13r,14s,17r)-5,14-dihydroxy-3-[(2r,4s,5r,6r)-5-hydroxy-4-methoxy-6-methyl-tetrahydropyran-2-yl]oxy-13-methyl-17-(5-oxo-2h-furan-3-yl)-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-10-carbaldehyde
mfcd00003669
AKOS030503859
NCGC00169509-02
Q5199357
DB13240
(3s,5s,9s,10s,13r,14s,17r)-5,14-dihydroxy-3-((2r,4s,5r,6r)-5-hydroxy-4-methoxy-6-methyltetrahydro-2h-pyran-2-yloxy)-13-methyl-17-(5-oxo-2,5-dihydrofuran-3-yl)hexadecahydro-1h-cyclopenta[a]phenanthrene-10-carbaldehyde
bdbm50255121
HY-111934
DTXSID20871714
CS-0094132
nsc7522 ,
wv 90043 a
k-strophanthin-.alpha.
5.beta.-card-20(22)-enolide,14-dihydroxy-19-oxo-
alvonal mr
5.beta., 3.beta.,5,14-trihydroxy-19-oxo-, 3-cymaroside
alvonal
b 652272k044
nsc-7522
cymarine
wln: l e5 b666tj avh e1 iq mq f- dt5ov ehj& oo- ft6otj b1 cq do1
NCI60_041646
PD011570

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" MTX, a non-mutagen, which induced SCE only at toxic levels, could be considered a false positive because this positivity may reflect an enhancement of incorporation of 5-BrdUrd into DNA."( Relationship between cytotoxicity and induction of sister-chromatid exchanges in mouse foetal cells exposed to several doses of carcinogenic and non-carcinogenic chemicals.
Faggin, P; Maconi, A; Parodi, S; Raffetto, G, 1979
)
0.26

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The results show that acetylation was successful in converting the poorly absorbed glycoside, cymarol, into a derivative that was rapidly absorbed from the peritoneal cavity."( Cardenolide analogues. VI. The metabolism of the prodrug diacetylcymarol in the rat.
Boutagy, J; Thomas, R, 1977
)
0.26

Dosage Studied

ExcerptRelevanceReference
" After intraperitoneal premedication with Strophanthin k in a therapeutical dosage (2 X 10(-5 g/kg body weight), the increase in number and extent of the necroses is statistically significant."( [Experimental heart muscle necorses in the rat after administration of 1-noreadrenaline and strophanthin. Light- and electron microscopic studies (author's transl)].
Büsing, CM; Kreisen, U, 1975
)
0.25
" Nicardipine at 10(-7) mol/l shifted to the right the dose-response curve for Ca of the phasic contraction evoked by electrical stimulation with an alternating current, and at higher concentration it reduced the maximum tension and slope of the dose-response curve."( Calcium antagonistic properties of nicardipine, a dihydropyridine derivative assessed in isolated cerebral arteries and cardiac muscle.
Ishii, K; Kato, H; Kurihara, J; Miyajima, Y; Nakayama, K, 1985
)
0.27
" Extensive dose-response experiments were performed using compounds that increased apoA-I transcription by minimally 20%."( Large-Scale Screening of Natural Products Transactivating Peroxisome Proliferator-Activated Receptor α Identifies 9S-Hydroxy-10E,12Z,15Z-Octadecatrienoic Acid and Cymarin as Potential Compounds Capable of Increasing Apolipoprotein A-I Transcription in Hum
Bendik, I; Böhlendorf, B; Konings, MCJM; Mensink, RP; Plat, J; Popeijus, HE; Tayyeb, J; van der Krieken, SE, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
cardenolide glycosideAny member of the class of cardenolides with glycosyl residues attached to position 3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sodium/potassium-transporting ATPase subunit beta-1 Rattus norvegicus (Norway rat)IC50 (µMol)0.01200.00240.64654.3000AID1455007
Sodium/potassium-transporting ATPase subunit alpha-4Rattus norvegicus (Norway rat)IC50 (µMol)0.01200.00180.00520.0120AID1455007
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1455007Inhibition of recombinant rat Na+/K+-ATPase alpha4/beta1 expressed in baculovirus infected insect Sf9 cell membranes using [gamma-32P]ATP as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins in presence of Na+, K+ an2018Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5
Design, Synthesis, and in Vitro and in Vivo Evaluation of Ouabain Analogues as Potent and Selective Na,K-ATPase α4 Isoform Inhibitors for Male Contraception.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (67)

TimeframeStudies, This Drug (%)All Drugs %
pre-199053 (79.10)18.7374
1990's2 (2.99)18.2507
2000's2 (2.99)29.6817
2010's6 (8.96)24.3611
2020's4 (5.97)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.16 (24.57)
Research Supply Index4.39 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index29.80 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials2 (2.56%)5.53%
Reviews1 (20.00%)6.00%
Reviews1 (1.28%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
Other75 (96.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]